A specialized laboratory has been established at N. D. Zelinsky Institute of Organic Chemistry of the Russian Academy of Sciences (IOC RAS) with the financial and organizational support of the R-Pharm group of companies, which will focus on the development of conjugated carbohydrate vaccines (the so-called glycovaccines) against antibiotic-resistant nosocomial diseases.
Among other things, R-Pharm will take part in biological testing of high-tech products being developed.
The development of glycovaccines is especially relevant due to the increasing number of resistant pathogens, primarily bacteria, fungi, and yeast. To expand research activities in this direction, a laboratory of synthetic glycovaccines has been created on the basis of the group led by Candidate of Chemical Sciences Vadim Krylov in the Laboratory of Chemistry of Glycoconjugates of the IOC RAS, headed by corresponding member of the Russian Academy of Sciences Nikolai Nifantiev. The application for the creation of the laboratory won a grant in a contest for youth laboratories recently held by the Ministry of Education and Science of Russia. The R-Pharm Group of Companies, which has been actively cooperating with the IOC RAS in this field for more than five years, acts as an industrial partner in this project as well.
“The development of glycovaccines remains one of the most promising areas in the search for effective ways to counteract resistant pathogens. We have been interacting with the Institute’s team for quite a while and are well aware of the capabilities of the project team, and we expect that our joint efforts will produce the necessary results,” said Vasily Ignatiev, General Director of R-Pharm.
“Glycovaccines are able to fight many dangerous pathogens, including Pneumococcus, aspergillosis, Pseudomonas aeruginosa. Our institute has already made great progress in the development of conjugated vaccines and the deployment of technologies for the preparation of currently used carrier proteins, but the financial and organizational support of such an industrial partner as R-Pharm will allow us to take this work to a new level,” said Nikolai Nifantiev, Corresponding Member of the Russian Academy of Sciences.
